BioLineRx Ltd. (NASDAQ:BLRX) received a $3.00 price target from Maxim Group in a research report issued on Monday, July 10th. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective suggests a potential upside of 154.24% from the company’s previous close.
BLRX has been the topic of a number of other reports. HC Wainwright set a $4.00 target price on BioLineRx and gave the company a “buy” rating in a research note on Tuesday, April 18th. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “hold” rating in a report on Friday, May 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $2.59.
Shares of BioLineRx (BLRX) traded up 3.51% on Monday, reaching $1.18. 1,123,323 shares of the company’s stock were exchanged. BioLineRx has a one year low of $0.79 and a one year high of $1.42. The firm’s market capitalization is $72.90 million. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $0.96.
BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, equities research analysts predict that BioLineRx will post ($0.25) EPS for the current year.
Several large investors have recently made changes to their positions in the stock. Sabby Management LLC acquired a new position in shares of BioLineRx during the first quarter valued at approximately $3,018,000. KCG Holdings Inc. increased its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares in the last quarter. Benchmark Capital Advisors increased its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of BioLineRx during the first quarter valued at approximately $126,000. Finally, Citadel Advisors LLC increased its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares in the last quarter. Institutional investors and hedge funds own 34.91% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with our FREE daily email newsletter.